Vishal Agrawal

Vishal Agrawal

Auto-generated profile, based on publicly available information

Vishal Agrawal

Department of Pediatrics, University of California, San Francisco, California 94143-0978, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2005 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
NHNingwu Huang
Ningwu Huang
Amit V PandeyAmit V Pandey
Amit V Pandey
VAVishal Agrawal
Vishal Agrawal
WRWilliam Reardon
William Reardon
PLPablo Lapunzina
Pablo Lapunzina
WMWalter L. Miller
Walter L. Miller

5 February 2008 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
NHNingwu Huang
Ningwu Huang
VAVishal Agrawal
Vishal Agrawal
KGKathleen M. Giacomini
Kathleen M. Giacomini
WMWalter L. Miller
Walter L. Miller
P450 oxidoreductase (POR) is an electron-donating flavoprotein required for the activity of all microsomal cytochrome P450 enzymes. We sequenced 5,655 bp of the POR gene in a representative population of 842 healthy unrelated individuals in four ethnic groups: 218 African Americans, 260 Caucasian Americans, 179 Chinese Americans, and 185 Mexican Americans. One hundred forty SNPs were detected, of which 43 were found in ≥1% of alleles. Twelve SNPs were in the POR promoter region. Fifteen of 32 exonic variations altered the POR amino acid sequence; 13 of these 15 are previously undescribed missense variations. We found eight indels, only one of which was in the coding region. A previously described variant, A503V, was found on 27.9% of all alleles with some ethnic predilection (19.1% in African Americans, 26.4% in Caucasian Americans, 36.7% Chinese Americans, and 31.0% in Mexican Americans). We built cDNA expression vectors for the 13 previously undescribed missense variants, expressed each protein lacking 27 N-terminal residues in Escherichia coli , and assayed the apparent K m and V max of each in four assays: reduction of cytochrome c , oxidation of NADPH, 17α-hydroxylase activity of P450c17, and 17,20 lyase activity of P450c17. The catalytic activities of several missense mutants differed substantially in these assays, indicating that each POR mutant must be assayed separately with each potential target P450 enzyme. The activity of A503V was reduced to a modest but statistically significant degree in all four assays, suggesting that it may play an important role in interindividual variation in drug response.

1 August 2004 in Archives of Biochemistry and Biophysics
Verified
Journal Article
Closed access
ASAnshuman Shukla
Anshuman Shukla
SMSourav Mukherjee
Sourav Mukherjee
SSSwati Sharma
Swati Sharma
VAVishal Agrawal
Vishal Agrawal
KKK.V Radha Kishan
K.V Radha Kishan
PGP Guptasarma
P Guptasarma

1 July 2008 in Pharmacogenetics and Genomics
Verified
Journal Article
Closed access
VAVishal Agrawal
Vishal Agrawal
NHNingwu Huang
Ningwu Huang
WMWalter L. Miller
Walter L. Miller
All microsomal cytochrome P450s enzymes, including those that metabolize the majority of clinically used drugs, require electron transfer through P450 oxidoreductase (POR). Mutations in human POR cause altered steroidogenesis and congenital malformations, but the clinical effects on drug metabolism are unclear. We examined the effects of POR sequence variants on two drug-metabolizing P450 enzymes, CYP1A2 and CYP2C19. Our previous sequencing of the human POR gene in POR-deficient patients and in 842 normal individuals identified 35 sequence variants. We expressed these 35 POR sequence variants in bacteria, reconstituted them with the CYP enzymes in vitro, and assayed their activities with human CYP1A2 and CYP2C19. POR variants affected the activities of these enzymes to different extents. Disease-causing POR mutations A287P and R457H diminished catalysis by CYP1A2 and CYP2C19 to barely detectable levels. POR A503V, a polymorphism found in 28% of alleles in the normal population, had 85% of wild-type activity with CYP1A2 and 113% of wild-type activity with CYP2C19. Q153R, a disease-causing mutation that severely impaired steroidogenic activity and cytochrome c reduction, increased the activity of CYP1A2 to 144% and CYP2C19 activity to 284% of control. The activity of individual POR mutants may vary greatly depending on the electron recipient used to assay activity. Thus, the activity of a POR mutant to support catalysis by a particular P450 enzyme cannot be predicted by the activity of that POR mutant in an assay with a different P450 or with cytochrome c.

1 October 2010 in Pharmacogenetics and Genomics
Verified
Journal Article
Closed access
VAVishal Agrawal
Vishal Agrawal
JCJi Ha Choi
Ji Ha Choi
KGKathleen M. Giacomini
Kathleen M. Giacomini
WMWalter L. Miller
Walter L. Miller
Objectives CYP3A4 receives electrons from P450 oxidoreductase (POR) to metabolize about 50% of clinically used drugs. There is substantial inter-individual variation in CYP3A4 catalytic activity that is not explained by CYP3A4 genetic variants. CYP3A4 is flexible and distensible, permitting it to accommodate substrates varying in shape and size. To elucidate the mechanisms of variability in CYP3A4 catalysis, we examined the effects of genetic variants of POR, and explored the possibility that substrate-induced conformational changes in CYP3A4 differentially affect the ability of POR variants to support catalysis. Methods We expressed human CYP3A4 and four POR variants (Q153R, A287P, R457H, A503 V) in bacteria, reconstituted them in vitro and measured the Michaelis constant and maximum velocity with testosterone, midazolam, quinidine and erythromycin as substrates. Results POR A287P and R457H had low activity with all substrates; Q153R had 76–94% of wild-type (WT) activity with midazolam and erythromycin, but 129–150% activity with testosterone and quinidine. The A503 V polymorphism reduced the CYP3A4 activity to 61–77% of WT with testosterone and midazolam, but had nearly WT activity with quinidine and erythromycin. Conclusion POR variants affect CYP3A4 activities. The impact of a POR variant on catalysis by CYP3A4 is substrate-specific, probably because of substrate-induced conformational changes in CYP3A4.

1 December 2009 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
TSTaninee Sahakitrungruang
Taninee Sahakitrungruang
NHNingwu Huang
Ningwu Huang
MTMeng Kian Tee
Meng Kian Tee
VAVishal Agrawal
Vishal Agrawal
WRWilliam E. Russell
William E. Russell
WMWalter L. Miller
Walter L. Miller
Context: P450 oxidoreductase (POR) deficiency causes disordered steroidogenesis; severe mutations cause genital ambiguity in both sexes plus the Antley-Bixler skeletal malformation syndrome, whereas mild mutations can cause adult infertility. Objective: We describe four patients with POR deficiency and identify and characterize the activities of their mutations. A 46,XY male with micropenis and two 46,XX female infants with genital ambiguity presented with skeletal malformations, and a 46,XX adolescent presented with primary amenorrhea, elevated 17α-hydroxyprogesterone, and low sex steroids. Methods: The coding regions of the POR gene were sequenced, and the identified mutations were recreated in human POR cDNA expression vectors lacking 27 N-terminal residues. POR and human P450c17 were expressed in bacteria. POR activity was measured by four assays: reduction of cytochrome c, oxidation of reduced nicotinamide adenine dinucleotide phosphate, and support of the 17α-hydroxylase and 17,20 lyase activities of P450c17. Results: All four patients were compound heterozygotes for POR mutations, including five novel mutations: L577R, N185K, delE217, and frameshift mutations 1363delC and 697–698insGAAC. N185K and delE217 lacked measurable activity in the assays based on P450c17 but retained partial activity in the assays based on cytochrome c. As assessed by Vmax/Km, L577R supported 46% of 17α-hydroxylase activity but only 27% of 17,20 lyase activity. Computational modeling of these novel mutants revealed the structural basis for their reduced or absent activities. Conclusion: These patients illustrate the broad clinical spectrum of POR deficiency, including amenorrhea and infertility as the sole manifestation. POR assays based on P450c17 correlate well with hormonal and clinical phenotypes.